Subject Index

Acitretin, skin cancer chemoprevention 66
Actinic keratosis (AK)
  immunosuppression agent selection for prevention 44
  management 60
  progression prevention 187, 188
  screening in transplant candidates 58
  topical therapy for prevention 61
Acute generalized exanthematic pustulosis, drug hypersensitivity reaction 157
Adnexal tumors, transplant patients 26
AFX, see Atypical fibroxanthoma
AK, see Actinic keratosis
Alefacept, immunosuppression agent prospects 76, 77
Anaphylaxis, drug hypersensitivity reaction 156
Angioedema, drug hypersensitivity reaction 154
Anti-thymocyte globulin (ATG), immunosuppression and side effects 42, 43
ATG, see Anti-thymocyte globulin
Atypical fibroxanthoma (AFX), transplant patients 30
Avascular bone necrosis, hematopoietic stem cell transplantation late effect 142, 143
Azathioprine
  metabolism 40
  photosensitization 41, 65
  squamous cell carcinoma risks 6, 40
Basal cell carcinoma (BCC)
  basosquamous carcinoma 22, 23
  epidemiology in organ transplantation 22
  genetics 23
  histology 22, 23
  management 23, 24, 63
  screening in transplant candidates 58
BCC, see Basal cell carcinoma
BD, see Bowen's disease
Belatacept, immunosuppression agent prospects 76
Belimumab, immunosuppression agent prospects 75
Bone marrow transplantation, see Hematopoietic stem cell transplantation
Bortezomibe, immunosuppression agent prospects 77
Bowen's disease (BD)
  management 60
  screening in transplant candidates 58
Calcineurin inhibitors, see Cyclosporin A; Tacrolimus
Candida albicans, skin infection with immunosuppression 14
Capecitabine, skin cancer chemoprevention 66, 67
Cardiovascular disease (CVD), hematopoietic stem cell transplantation late effect 141, 142
Caries, hematopoietic stem cell transplantation late effect 140
Chronic kidney disease, hematopoietic stem cell transplantation late effect 142
Corticosteroids, see Glucocorticoids
CVD, see Cardiovascular disease
Cyclosporin A
  cutaneous side effects 40
  graft-versus-host disease management 108, 109
  mechanism of immunosuppression 39, 40
  sparing studies 73
  squamous cell carcinoma risks 6
Diclofenac, topical therapy for squamous cell carcinoma prevention 61
Drug hypersensitivity reactions, hematopoietic stem cell transplantation clinical manifestations acute generalized exanthematic pustulosis 157
anaphylaxis 156
angioedema 154
drug hypersensitivity syndrome 157, 158
erythema exsudativum multiforme 158
erythema nodosum 160, 161
fever 154
general symptoms 154
interstitial granulomatous drug reaction 160
lichen planus 160
maculopapular exanthema 156, 157
psoriasis 159, 160
Stevens-Johnson syndrome 158
stomatitis 159
Sweet's syndrome 161
table 155, 156
toxic epidermal necrolysis 158, 159
urticaria 154
vasculitis 159
diagnosis 161, 162
differential diagnosis graft-versus-host disease 153
infectious exanthema 151, 152
eliciting drugs 161
overview 150, 151

ECP, see Extracorporeal photoforesis
EEM, see Erythema exsudativum multiforme
ELR, see Eruption of lymphocyte recovery
Epidermodysplasia verruciformis (EV) beta human papillomavirus role 50
genetics 50, 51
Eruption of lymphocyte recovery (ELR), drug hypersensitivity reaction differential diagnosis 153
Erythema exsudativum multiforme (EEM), drug hypersensitivity reaction 158
Erythema nodosum, drug hypersensitivity reaction 160, 161
EV, see Epidermodysplasia verruciformis
EVER proteins, function 12, 51
Extracorporeal photophoresis (ECP), chronic graft-versus-host disease management adult patient outcomes 123–125
mechanism of action 122, 123
pediatric patient outcomes 126–128
sclerotic-type disease outcomes 125, 126
steroid-sparing effect in hematopoietic stem cell transplantation 128

Fever, drug hypersensitivity reaction 154
Filaggrin, barrier function 10

Glucocorticoids avoidance or withdrawal 72
cutaneous side effects 39
graft-versus-host disease management systemic therapy 108
topical therapy 107, 108
mechanism of immunosuppression 39
Graft-versus-host disease (GVHD) cellular therapy 168, 169
drug hypersensitivity reaction differential diagnosis 153
late organ dysfunction role 142, 143
National Institutes of Health consensus project 166
GVHD, see Graft-versus-host disease

HCQ, see Hydroxychloroquine
Health consensus project 166
acute disease 102, 103
acute disease and T cell populations naive T cells 94
regulatory T cells 94
Th17 cells 94
changing concepts 88, 89
chronic disease 84, 91, 96, 97, 103–107, 165–167
chronic graft-versus-host disease consortium 166, 167
clinical significance 165, 166
management extracorporeal photophoresis for chronic disease adult patient outcomes 123–125
mechanism of action 122, 123
pediatric patient outcomes 126–128
sclerotic-type disease outcomes 125, 126
steroid-sparing effect in hematopoietic stem cell transplantation 128

Downloaded by: 54.70.40.11 - 10/2/2017 10:57:22 AM
immunosuppression effects 2, 3
Isotretinoin, skin cancer chemoprevention 66

Kaposi sarcoma (KS)
histology 28, 29
human herpesvirus 8 role 28, 29
human immunodeficiency virus patients 15, 17
immunosuppression agent selection for prevention 45, 64
management 63, 64
transplant patients 11, 14, 28–30
KS, see Kaposi sarcoma

Langerin, function 10
Lichen planus, drug hypersensitivity reaction 160

Lymphoma, posttransplant lymphoproliferative disorders 30, 31

Maculopapular exanthema, drug hypersensitivity reaction 156, 157
Malignant melanoma, see Melanoma
Mammalian target of rapamycin (mTOR), inhibitors as immunosuppressants 41, 42, 44, 65
MCC, see Merkel cell carcinoma
Melanoma
epidemiology in organ transplantation 26, 27
histology 27
immunosuppression agent selection for prevention 45
management 63
prognosis 27
Merkel cell carcinoma (MCC)
epidemiology in organ transplantation 24
histology 24, 25
immunosuppression agent selection for prevention 56
management 64
markers 24
metastasis 26
viral causation 26
Mesenchymal stem cell (MSC), graft-versus-host disease management 111, 112
MMF, see Mycophenolate mofetil
MSC, see Mesenchymal stem cell
mTOR, see Mammalian target of rapamycin
Mycophenolate mofetil (MMF)
cutaneous side effects 41
graft-versus-host disease management 109
mechanism of immunosuppression 41

OKT3, immunosuppression and side effects 42, 43
Osteoporosis, hematopoietic stem cell transplantation late effect 139, 140

Photodynamic therapy, squamous cell carcinoma prevention 61
Photoprotection
clothing 76
environmental photoprotection 175, 176
sunscreen
controversies 180
efficacy 181
inorganic agents 177
organic agents 177, 178
quality factors 180
safety
absorption and endocrine effects 182, 183
adverse reactions 181, 182
vitamin D deficiency 182
sun protection factor 183, 184
ultraviolet absorbers 176–179
vehicle selection and formulation 179, 180
water resistance 184, 185

transplant recipient skin cancer prevention
educational and behavioral aspects 189, 190
overview 58, 59, 171–173
premalignant lesion progression prevention 187, 188
primary prevention 187
second primary tumor prevention 188, 189

ultraviolet radiation
biological effects 174
classification 173, 174
immunosuppression 175
lifetime ultraviolet dose 185, 186

Pityrosporum folliculitis 3
Posttransplant lymphoproliferative disorders (PTLD), skin manifestations 30, 31
Psoriasis, drug hypersensitivity reaction 159, 160
PTLD, see Posttransplant lymphoproliferative disorders
Reduced intensity conditioning (RIC), hematopoietic stem cell transplantation late effect prevention 143–145
Retinoids, see also specific retinoids
  graft-versus-host disease management 111
  skin cancer chemoprevention 66
RIC, see Reduced intensity conditioning
Rituximab
  graft-versus-host disease management 110
  immunosuppression agent prospects 74, 75
Sarcoma, transplant patients 30
SCC, see Squamous cell carcinoma
Sirolimus, graft-versus-host disease management 109
SJS, see Stevens-Johnson syndrome
Skin cancer, see Adnexal tumors; Basal cell carcinoma; Kaposi sarcoma; Lymphoma; Melanoma; Merkel cell carcinoma; Squamous cell carcinoma
Squamous cell carcinoma (SCC)
  basosquamous carcinoma 22, 23
  chemoprevention 66, 67
  high-risk squamous cell carcinoma 62, 63
  histology 19–21
  human papillomavirus association 52, 53
  immunosuppression agent selection for prevention 44, 45, 64, 65
  immunosuppression effects 4–6
  integrated care 67
  management 21, 22, 44, 59–61
  pathogenesis 21
  photodamage in organ transplantation recipients 3, 4, 6
  precursors 19, 20
  screening in transplant candidates 58
  topical therapy for prevention 61
  variants 21
Stevens-Johnson syndrome (SJS), drug hypersensitivity reaction 158
Stomatitis, drug hypersensitivity reaction 159
Sun protection factor, see Photoprotection
Sunscreen, see Photoprotection
Sweet's syndrome, drug hypersensitivity reaction 161
T cell, graft-versus-host disease activation and costimulation 92, 93
  acute disease T cell populations
    naïve T cells 94
    regulatory T cells 94
    Th17 cells 94
  effector stage 95, 96
  trafficking 95
Tacrolimus
  cutaneous side effects 40
  graft-versus-host disease management 108, 109
  mechanism of immunosuppression 39, 40
  squamous cell carcinoma risks 6
TEN, see Toxic epidermal necrolysis
Thalidomide, graft-versus-host disease management 111
Toxic epidermal necrolysis (TEN), drug hypersensitivity reaction 158, 159
Ultraviolet A1 phototherapy, chronic graft-versus-host disease management
  mechanism of action 120
  outcomes 118, 119
  overview 117, 118
  side effects 120, 121
  technique 121, 122
Ultraviolet protection, see Photoprotection
Urticaria, drug hypersensitivity reaction 154
Vasculitis, drug hypersensitivity reaction 159
Vitamin D
  status in transplant patients 59
  sunscreen and deficiency 182
Voriconazole, skin cancer risks 65